Diseases & Conditions
Grants & Contracts
News & Events
Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.
The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.
An overview of the NIAID-supported Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) at The Duke University School of Medicine.
The George Mason University Center for Infectious Disease Research Biomedical Research Laboratory (BRL) is one of the NIAID-supported Biocontainment Laboratories. The RBL supports research programs in the Center for Infectious Disease Research focusing on host response using proteomics and nanote
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms u
The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.